British drug giant GlaxoSmithKline (NYSE: GSK) is planning more restructuring in Europe, a response to sinking profits. The restructuring is expected to save the company - which has its U.S. headquarters in Research Triangle Park - at least $1.57 billion by 2016. CEO Andrew Witty wouldn’t say how many jobs would be cut as part of the plan. He did say that investing in new manufacturing and research technology would be a big part of the restructuring. The move comes after GSK announced a 31 percent…
Reported by bizjournals 3 hours ago.
↧